VERA News and Press, Vera Therapeutics Inc. From 01/12/24

2024-01-12 09:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the appointments of two industry veteran...

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced it will host an in-person R&D day fe...

2023-12-29 01:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s man...

2023-12-15 10:15:00 ET Investing in small-cap stocks comes with inherent risks. These stocks are, after all, fairly small in size because they are relatively unproven businesses. Often, they aren't profitable or even generating revenue, which can normally be the case when it comes to ...

2023-11-10 10:34:03 ET More on Vera Therapeutics Vera Therapeutics' Promising Atacicept Drug Targets IgAN Guggenheim starts Vera at buy, sees IgAN drug as "well positioned" Seeking Alpha’s Quant Rating on Vera Therapeutics Historical earnings data for ...

2023-11-09 13:15:35 ET More on Vera Therapeutics Vera Therapeutics' Promising Atacicept Drug Targets IgAN Guggenheim starts Vera at buy, sees IgAN drug as "well positioned" Seeking Alpha’s Quant Rating on Vera Therapeutics Historical earnings data for ...

Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgAN Announced analysis of Phase 2b ORIGIN study showing resolution of hematuria in the majority of patients,...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...